Ultime notizie per BioVie (NASDAQ:BIVI) Azioni

BioVie

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

News

During Conf Call, AT&T Says Expects Postpaid Phone Churn To Follow Seasonal Patterns In The Back Half Of 2025; "Assuming That We're Going To Continue To Have A Competitive Environment"; Prepaid Market In Q2 Has Some Impact From Immigration Changes

Wells Fargo analyst Colin Langan maintains General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) with a Underweight and raises the price target from $34 to $38.

Price Target

Analyst Ratings

Wells Fargo Maintains Underweight on General Motors, Raises Price Target to $38

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.knightscope.com%2F&amp;esheet=54294939&amp;newsitemid=20250723378047&amp;lan=en-US&amp;anchor=Knightscope%2C+Inc.&amp;index=1&amp;md5=23f1915843dc8ad701609a9ea84f2b73">Knightscope, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KSCP#NASDAQ">KSCP</a>), a leader in autonomous security robots and emergency communication devices, today announced that it has surpassed another $1.3 million in new contracts, including major client renewals, strategic expansions, and new sales wins nationwide. This growth underscores the sustained demand for smarter and more secured environments.

KSCP

Knightscope Secures $1.3M In New Contracts, Reflecting Continued Demand For Smarter Security Solutions Nationwide

Wells Fargo analyst Jason Haas maintains MSCI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSCI#NYSE">MSCI</a>) with a Equal-Weight and lowers the price target from $578 to $533.

MSCI

Wells Fargo Maintains Equal-Weight on MSCI, Lowers Price Target to $533

RBC Capital analyst Shagun Singh maintains Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) with a Outperform and raises the price target from $605 to $615.

ISRG

RBC Capital Maintains Outperform on Intuitive Surgical, Raises Price Target to $615

The U.K.&#8217;s Competition and Markets Authority (CMA) is proposing significant changes to the mobile ecosystems of&nbsp;Apple Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) and&nbsp;Google, a subsidiary of&nbsp;Alphabet Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>), following an investigation into their market dominance.
What Happened: The CMA is considering designating Apple and Google with "strategic market status"  or SMS, a status given to companies with substantial and entrenched market power in the UK&#8217;s digital activities. This could lead to changes in their app stores and mobile ecosystems, CNBC <a href="https://www.cnbc.com/2025/07/23/apple-google-uk-competition-regulator-investigation.html">reported</a>. The CMA has been investigating the matter since January.
The CMA's investigation examined whether Apple and Google's mobile platforms create obstacles that hinder competitors from providing alternative products and services. It also looked into whether the tech giants are using their position to favor their own apps and services and if they impose unfair terms and conditions on developers.
The CMA has identified several consumer and business concerns, including inconsistent app review processes, unpredictable app store search rankings, and&nbsp;the up to 30% commission&nbsp;charged by Apple and Google on some in-app purchases.
Google&#8217;s Android operating system holds over 61% of the UK market share, while Apple&#8217;s iOS has just over 38%. The CMA has proposed immediate and long-term changes, including a review of app distribution processes and the possibility of allowing alternative app stores on iOS.
See Also: <a href="https://benzinga.com/news/politics/25/07/46568764/obama-slams-trumps-coup-allegations-over-2016-election-as-outrageous-and-ridiculous-in-rare-public-rebuke" target="_blank" rel="noreferrer noopener">Barack Obama Hits Back At Trump&#8217;s &#8216;Outrageous&#8217; Accusations Of Treason And Coup, Calls It &#8216;Weak Attempt At Distraction&#8217;</a>
Why It Matters: The CMA&#8217;s move is part of a broader trend of European regulators scrutinizing big tech companies. On Wednesday, it was reported that Apple was&nbsp;<a href="https://www.benzinga.com/markets/tech/25/07/46565660/apple-set-to-dodge-over-50-million-in-daily-eu-fines-with-app-store-overhaul-opening-door-to-cheaper-developer-payments-report">likely to avoid</a> daily fines&nbsp;from the EU by accepting changes to its App Store rules and fees.
In June,&nbsp;Apple <a href="https://www.benzinga.com/markets/tech/25/06/46133145/apple-opens-eu-app-store-to-external-payments-to-avoid-fines-under-digital-markets-act-but-adds-new-fees">announced new terms</a>&nbsp;allowing developers in the EU to promote external purchase offers, a significant compliance step under the Digital Markets Act. 
Meanwhile,&nbsp;<a href="https://www.benzinga.com/markets/tech/25/06/46041525/google-offers-to-boost-rivals-in-search-results-to-avoid-eu-antitrust-fine-under-digital-markets-act-report">Google offered to boost rivals</a>&nbsp;in its search results to avoid a hefty fine from the EU. These developments indicate that European regulators are taking a more proactive approach to ensure fair competition in the tech industry.
On a year-to-date basis, Apple dropped 11.97%, while Google edged 0.86% higher, as per <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/entertainment/25/07/46549276/apple-stock-to-get-soccer-boost-ted-lasso-starts-filming-season-4">Apple Stock To Get Soccer Boost? &#8216;Ted Lasso&#8217; Starts Filming Season 4</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

AAPL

GOOG

GOOGL

Apple, Google Face Sweeping UK Antitrust Crackdown As Competition Regulator Targets 'Strategic Market Status' Over App Store Control

<a href="https://truthsocial.com/@realDonaldTrump/posts/114902814296069974" title="https://truthsocial.com/@realDonaldTrump/posts/114902814296069974">https://truthsocial.com/@realDonaldTrump/posts/114902814296069974</a>

Macro Economic Events

Politics

Global

Economics

General

President Trump Posts On X "I WILL ONLY LOWER TARIFFS IF A COUNTRY AGREES TO OPEN ITS MARKET. IF NOT, MUCH HIGHER TARIFFS! Japan's Markets are now OPEN (for first time ever!). USA BUSINESSES WILL BOOM!"

Wells Fargo analyst Jason Haas maintains Equifax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFX#NYSE">EFX</a>) with a Overweight and lowers the price target from $310 to $300.

Wells Fargo Maintains Overweight on Equifax, Lowers Price Target to $300

Susquehanna analyst Christopher Rolland maintains Texas Instruments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) with a Positive and lowers the price target from $250 to $240.

Susquehanna Maintains Positive on Texas Instruments, Lowers Price Target to $240

<a href="https://www.linkedin.com/posts/fuelcell-energy_innovationfund-activity-7353774197560483843-wDkJ/?utm_source=share&amp;utm_medium=member_desktop&amp;rcm=ACoAAB8wy38BEh70rZDOPuMUdcFYN__XtZA5lDM">https://www.linkedin.com/posts/fuelcell-energy_innovationfund-activity-7353774197560483843-wDkJ/?utm_source=share&amp;utm_medium=member_desktop&amp;rcm=ACoAAB8wy38BEh70rZDOPuMUdcFYN__XtZA5lDM</a>
As outlined by ExxonMobil: "Scientists at ExxonMobil and FuelCell Energy, Inc. are jointly pursuing new technology that could reduce the costs associated with current CCS processes by increasing the amount of electricity a power plant produces while simultaneously delivering significant reductions in carbon dioxide emissions. Laboratory tests have indicated that applying carbonate fuel cells to natural gas power generation could capture carbon dioxide more efficiently than current, conventional CCS technology. In fact, our research indicates that by applying this new technology, more than 90 percent of a natural gas power plant's carbon dioxide emissions could be captured."

FCEL

'FuelCell Energy is excited to see continued progress on this carbon capture and storage (CCS) initiative with ExxonMobil Benelux.' - LinkedIn Post From FuelCell Energy

RBC Capital analyst Keith Mackey maintains Halliburton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) with a Sector Perform and lowers the price target from $28 to $24.

RBC Capital Maintains Sector Perform on Halliburton, Lowers Price Target to $24

Susquehanna analyst Biju Perincheril maintains SM Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SM#NYSE">SM</a>) with a Neutral and raises the price target from $24 to $27.

Susquehanna Maintains Neutral on SM Energy, Raises Price Target to $27

Wells Fargo analyst Brandon Couillard maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Equal-Weight and lowers the price target from $210 to $205.

Wells Fargo Maintains Equal-Weight on Danaher, Lowers Price Target to $205

Susquehanna analyst Mehdi Hosseini maintains Silicon Motion Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIMO#NASDAQ">SIMO</a>) with a Positive and raises the price target from $80 to $90.

SIMO

Susquehanna Maintains Positive on Silicon Motion Technology, Raises Price Target to $90

RBC Capital analyst Brad Heffern maintains Equity Lifestyle Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELS#NYSE">ELS</a>) with a Sector Perform and lowers the price target from $67 to $66.

RBC Capital Maintains Sector Perform on Equity Lifestyle Props, Lowers Price Target to $66

Susquehanna analyst Charles Minervino maintains RTX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) with a Positive and raises the price target from $160 to $175.

Susquehanna Maintains Positive on RTX, Raises Price Target to $175

Wells Fargo analyst Larry Biegelsen maintains Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) with a Overweight and raises the price target from $559 to $599.

Wells Fargo Maintains Overweight on Intuitive Surgical, Raises Price Target to $599

Susquehanna analyst Biju Perincheril maintains Range Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRC#NYSE">RRC</a>) with a Neutral and raises the price target from $36 to $39.

Susquehanna Maintains Neutral on Range Resources, Raises Price Target to $39

Wells Fargo analyst Stephen Baxter maintains Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) with a Overweight and lowers the price target from $372 to $216.

Wells Fargo Maintains Overweight on Molina Healthcare, Lowers Price Target to $216

RBC Capital analyst Mike Dahl maintains D.R. Horton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>) with a Underperform and raises the price target from $105 to $117.

RBC Capital Maintains Underperform on D.R. Horton, Raises Price Target to $117

Press Releases

BioVie Initiates SUNRISE-PD Clinical Trial Assessing Bezisterim in Early Parkinson's Disease with First Patient Enrolled

Legal

BIOVIE ALERT: Bragar Eagel & Squire, P.C. is Investigating BioVie Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Management

BioVie Unveils Corporate Advisory Board Featuring Neuralink Co-Founder, Former Executives from Mastercard and Apple, and High-Impact Industry Leaders to Advance BioVie Mission and Growth

BioVie to Present Rationale and Design of Phase 2 SUNRISE-PD Clinical Trial at the 30th World Congress on Parkinson's Disease and Related Disorders (IAPRD 2025)

Health Care

BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease on May 28, 2025

BioVie Enrolls First Patient in ADDRESS-LC Clinical Trial Assessing Novel Anti-Inflammatory Candidate Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID

BioVie to Present Overview of Phase 2 SUNRISE-PD Trial at the Advanced Therapeutics in Movement & Related Disorders® Congress

BioVie Highlights Patient-Centric Design of SUNRISE-PD Trial at Advanced Therapeutics in Movement & Related Disorders® Congress (ATMRD)

BioVie Announces Data Highlighting Bezisterim's Potential to Slow or Reverse Biological Aging and Neurodegeneration Featured as a Keynote Talk at the 7th World Aging and Rejuvenation Conference

Comments

BioVie

Notizie

Ultime notizie per BioVie (NASDAQ:BIVI) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO